Held by 7 specialist biotech funds
High Convergence# Signal Note: OrbiMed Initiates $27.9M Position in PRAX OrbiMed's new 94,500-share stake signals conviction in Praxis's clinical pipeline, likely centered on PRAX-114 (a potential first-in-class therapy for ultra-rare neuropsychiatric disorders) and upcoming Phase 2 readouts expected in 2024-2025.
AI analyst context — unlock full analysis
**Signal Note: Baker Bros. initiates major position in Praxis Precision Medicine (PRAX)** The reported position size of ~$332B is almost certainly a data error (likely reflecting an incorrect price or share count), but the core signal — Baker Bros. opening a new concentrated position in PRAX — is noteworthy given their track record of high-conviction bets ahead of clinical catalysts. Praxis's lead asset is ulixacaltamide (T-CALM), a T-type calcium channel modulator in Phase 3 for essential tremor (PRAX-562 study), with topline data expected in 2025, alongside earlier-stage programs in mood disorders (PRAX-403). Baker's entry pattern is consistent with positioning ahead of a pivotal readout in a CNS name with limited competitive overlap, though the filing data should be verified for accuracy before sizing conclusions are drawn.
+ 5more — see how much conviction went in
See the Full Story